Elite Pharmaceuticals Inc (QB) (ELTP) News

That's not true, ask "team pump" and you will get
outrageous fantasy numbers. All based on what they can punch in to the dream calculator....lol
It's been like that for years, hell, the team captain
says he's been buying every day since 2015.

Yes, exactly.

And yet you get garbage responses and don't even know it. I'd love to see the companies on which it's based. You still haven't been able to provide that just some number from the ether. 

In prompt engineering you need to be specific if you want precise answers.

If you ask for generic pharmaceutical companies producing and selling cns drugs and opioids. You will get a P/E ratio of about 24.

These are NOT generic only drug companies. That is why they have PEs in the 30s.
Generic drug companies right now are in the 11 to 14 range with many not having PEs because they are losing money. Many specialty drug companies that make their own drugs also develop generics. So you can't count these in the same category as Elite. Teva is an example, but many other generic drug companies have their own formulations that a much much more profitable than generics (Sun Pharma, Dr Reddy's etc).

1. Cipla Limited makes more than just generic drugs:
Antiretroviral drugs: Cipla is the world's largest manufacturer of antiretroviral drugs.
Personal care products: Cipla sells personal care products.
Heart disease drugs: Cipla has developed drugs to treat heart disease, including those for angina, heart failure, hypertension, arrhythmia, and lipid abnormalities.

2. Zoetis Inc. This isn't much of a generic drug company at all. It is the world's largest producer of medicine and vaccinations for pets and livestock. Zoetis Inc. is a global leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines, and diagnostic products. The invent their own drugs that get patents and are protected up until some point a generic drug company can start making them to.

3. Haleon Inc. Again not a generic drug company at all. Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England.[3] It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins.[4] The company was projected to be a global leader in over the counter medicines with a 7.3 percent market share in 2022.[5]

4. Neurocrine Biosciences, Inc. is not a generic drug company; it is considered a specialty pharmaceutical company focused on developing brand-name drugs for neurological and endocrine-related diseases, meaning they primarily create and market their own unique medications rather than generic versions of existing drugs.

Ask any of the AI agents (ChatGPT, google, Bing whatever) what is the average PE of a generic pharmacetical it will report some value between 11 and 15. With some description like so:
According to recent data, the average P/E ratio for generic pharmaceuticals is around 14.79. This is significantly lower than the broader pharmaceutical industry average, which tends to be higher due to the higher profit margins associated with brand-name drugs.

Here is an article from Jan 2025 that breaks down PE of only generic companies over the past 5 years.
https://www.nasdaq.com/articles/3-generic-drug-stocks-to-watch-amid-improving-market-prospects-1#:~:text=One%2DYear%20Price%20Performance&text=Based%20on%20forward%2012%20months,as%20the%20charts%20below%20show.

Based on forward 12 months price-to-earnings (P/E F12M), which is a commonly used multiple for valuing generic companies, the industry is currently trading at 11.24X compared with the S&P 500’s 20.31X and the Zacks Medical sector’s 22.89X.
Over the last five years, the industry has traded as high as 13.31X, as low as 7.02X, and at the median of 9.30X, as the charts below show.

Thank HGilS

Yes Arby. Please do.

Drug manufactures - General industry has a total of 19 stocks, with a combined market cap of $3,160 billion, total revenue of $676.65 billion and a weighted average PE ratio of 34.66.
According to recent study by nova one advisor, the U.S. generic drugs market size is projected to surpass around USD 188.44 billion by 2033 from USD 133.59 billion in 2023 and is expanding at a CAGR of 3.5% between 2024 to 2033.
Association for Accessible Medicines - Generics account for 90 percent of prescriptions dispensed in the U.S!

From general search of generics trading in USA, most are foreign companies trading NYSE and NASDAQ. Many have branded and generics of their own drugs as well as generics of other companies' generics. PE for companies in the world but traded on U.S. stock markets are all over the place but looking at quarterly analysis at various companies AbbVie Inc. (ABBV) 61, Viatris Inc. (VTRS) 28, Gilead Sciences, Inc. (GILD) 2023 was 17 current is 998 on yahoo finance, and Amneal Pharmaceuticals, Inc. (AMRX) current shows -- but last numbered quarterly was in Dec 2023 at 101.
Therefore I believe based on HGilS analysis that the PE is very low for ELTP and investors will lift it up!
HGilS, may I share your calculations on other boards?

Vyvanse Approval Nov 18th 2024
Vyvanse Launch Dec 26th 2024
Launch 2 weeks ago.
ELTP moving at light speed.
$20 + Million quarter imminent

It’s called hallucinations But I don’t know where you have been in the last five years.

The only stock on the otc that has been profitable for 5 years.

Revenues growing steadily.

The proof is in the pudding. Did you dream 18 months ago we would have touched 75 cents?

See you at the buyout.

And with all those tools you don't know what is fact from fiction. Technology only helps so much. 

Team pump in over drive...lol
Using fantasty figures will always look great.
Vyvanse flopped where have you been.

lol.

On my phone I have access to about 10 llm’s

I use chatgpt4 for convenience.

I do prompts, agents, and agents to agents only,

Devops ai, dev Ai, test ai, ba ai, pm ai,

lol.

Clearly the case. Going to be interesting to see how ours holds up. 

Nice try. I'm done buying. Haven't made a purchase for months. 

Your accusations are hiding your inability to move beyond chatGPT. 

Ok got it after all these posts. Just say you need more time to load up at under fifty cents.

I don’t think the competitors can get enough API to end the shortage of Vyvanse.
There API supplier is under performin’

I'd say revisit your assumptions that today's $0.50 price is only based on $71M in rev. 

All awesome news for sure. Vyvanse market will significantly shrink within the next year as API normalizes and generics really enter the market. We have a massive advantage here, but it is short lived. We can capture market gains long-term like Adderall, but will be at a drastically reduced price in 12-months to what we could price today. 

Good reminder on Vyvanse and others not having profit sharing. That is something I hadn't considered with modeling, but did assume higher margins due to Vyvanse. Profit split isn't huge with Adderall as most of rev is from mfg, but every little bit will help. 

That seems to make more sense. I’m going to do it another way.
Your both wrong.

$0.50. ……. X
———. =. ———-
$71 M. ….. $570 M

X=4.01

Thx $0.75 it is.

Jour my friend.

Since August (15-20 cents) elite is on its way to multiply its addressable market by 5 times. It is adding a new product line (opioids). It is a company that has api suppliers and api where other companies are dry. It is quadrupling its manufacturing capability. Vyvanse is more expensive by three or four times than adderall. It became officially a global supplier.

We were at .75 when dexcel announced its approval.

The new drugs do not have a profit sharing.

We were a 57 million per year company.

Enough said.

I have plenty of experience with companies going through M&A as well, but not in the generic pharma market. How many generic pharma acquisitions have you been a part of? Industry means everything. I'd love nothing more than seeing a huge multiple. This is neither a tech stock or a company that has brand drugs so margins are lower and barrier to entry isn't low, but isn't high either. 

That 8-12x is unrealisticly low for a growing company, in a growth market and a growing pipeline. To sell such a company, I would expect a minimum of 18x and as high as 25/26. I would expect this as I have significant experience in the selling and buying of companies. So, do your own DD and place your chips. You are in a growth market w a growing market share company in its infancy. There are very few of these companies out there. Gltl

Those weren't comparable companies. It wasn't research and neither are those PEs adding any value to dialogue. If you think they do, I wish you the best with your investments. 


 I really don't care what you do for a living, but I do know you rely way too heavily on chatGPT for research. That will only lead to trouble. 

Come on board playoffs r on! But honor you alls enthusiasm! We don't get no print! Someday! You comparisons will eventually be mind-blowing, too good not to get print, otc, strong re-occuring revenues, low debt/profitable

You asked for companies with a P/E ratio greater than 30. I found them.

Have at least the integrity to acknowledge that.

Manipulation does not work with me.

If only you knew what I do for a living you would not use ChatGPT against me lol

I didn't you did. Zoetis was in one of the companies you provided dude. Stop using ChatGPT as a resource. It isn't helping you if you don't understand where it fails. 

500 mil in revenues?..as Jour said, market is forward looking and it obviously doesn't agree with that figure..but what do I know?

To estimate the price per share of Elite Pharmaceuticals (ELTP) based on an annual revenue of $500 million, we can use the Price-to-Sales (P/S) ratio from their financial reports. The P/S ratio is calculated as:

\text{P/S Ratio} = \frac{\text{Market Cap}}{\text{Annual Revenue}}

From the search results, Elite Pharmaceuticals has a market cap of approximately $534.14 million and a revenue of $71.17 million for the last 12 months [A](https://www.marketbeat.com/stocks/OTCMKTS/ELTP/?copilot_analytics_metadata=eyJldmVudEluZm9fY2xpY2tTb3VyY2UiOiJjaXRhdGlvbkxpbmsiLCJldmVudEluZm9fbWVzc2FnZUlkIjoiRW9iZWZEZlhpeWtWRmJ4cEY1a25kIiwiZXZlbnRJbmZvX2NsaWNrRGVzdGluYXRpb24iOiJodHRwczpcL1wvd3d3Lm1hcmtldGJlYXQuY29tXC9zdG9ja3NcL09UQ01LVFNcL0VMVFBcLyIsImV2ZW50SW5mb19jb252ZXJzYXRpb25JZCI6InFaczlTOUJUZEJYVjJkZ3VEYXJoeSJ9&citationMarker=9F742443-6C92-4C44-BF58-8F5A7C53B6F1). However, since we're estimating based on $500 million revenue, we'll adjust the calculation accordingly.

First, let's find the P/S ratio:

\text{P/S Ratio} = \frac{534.14 \text{ million}}{71.17 \text{ million}} \approx 7.50

Now, using the P/S ratio to estimate the price per share:

\text{Estimated Price per Share} = \text{P/S Ratio} \times \text{Annual Revenue}



\text{Estimated Price per Share} = 7.50 \times 500 \text{ million} = 3,750 \text{ million}

Since the company has 1.07 billion shares outstanding:

\text{Estimated Price per Share} = \frac{3,750 \text{ million}}{1.07 \text{ billion}} \approx \$3.50

So, based on an annual revenue of $500 million, the estimated price per share of Elite Pharmaceuticals would be approximately **$3.50**.

What P/E ratio should be given to a company like elite pharmaceuticals based on November 15 sec filing

To determine an appropriate P/E ratio for Elite Pharmaceuticals based on their November 15, 2024 SEC filing, we need to consider several factors, including their financial performance, growth prospects, and industry benchmarks.

Elite Pharmaceuticals reported revenues of $71.17 million for the last 12 months and a market cap of approximately $534.14 million [A](https://bing.com/search?q=Elite+Pharmaceuticals+November+15+SEC+filing&copilot_analytics_metadata=eyJldmVudEluZm9fY29udmVyc2F0aW9uSWQiOiJxWnM5UzlCVGRCWFYyZGd1RGFyaHkiLCJldmVudEluZm9fbWVzc2FnZUlkIjoiQWphTGYyb2RRRXk2bjQ4RXdnaWhKIiwiZXZlbnRJbmZvX2NsaWNrRGVzdGluYXRpb24iOiJodHRwczpcL1wvYmluZy5jb21cL3NlYXJjaD9xPUVsaXRlK1BoYXJtYWNldXRpY2FscytOb3ZlbWJlcisxNStTRUMrZmlsaW5nIiwiZXZlbnRJbmZvX2NsaWNrU291cmNlIjoiY2l0YXRpb25MaW5rIn0%3D&citationMarker=9F742443-6C92-4C44-BF58-8F5A7C53B6F1). Using these figures, we can calculate their current P/E ratio:

\text{P/E Ratio} = \frac{\text{Market Cap}}{\text{Annual Revenue}} = \frac{534.14 \text{ million}}{71.17 \text{ million}} \approx 7.50

Given this information, a P/E ratio of **7.50** is a starting point. However, if Elite Pharmaceuticals is expected to grow significantly, investors might be willing to pay a higher price for its shares, resulting in a higher P/E ratio.

Would you like to explore potential growth factors or industry benchmarks to refine this estimate further?

Why do you think comparing elite to a pet drug company is fair?

I had a Jack Russel for 18 years and he did not take any tablet nor was he subscribed any drug…

You can’t compare humans and pets. On top of that drugs In Shortage.

That explains your .75 valuation. Stress is gone lol.

Thanks, but I don't think any of these are a close comparison. I can speak offhand about Zoetis. I have a veterinarian friend who works there. Used to be part of Pfizer until was spun off. They focus on animal science - DNA testing, blood glucose monitors, vitamins, injectables, a whole ton of great products, but nothing close to what Elite does. Their products would be patentable, which carry certain protections from competitors and therefore higher margins for several years. Zoetis is also a highly global organization. Elite is getting there, but you wouldn't include the entire global market for Adderall, when you're only in Israel without accounting for the ability, cost and time to enter those markets.

I still stand by the 8-12x historic generic pharma multiple. Would absolutely love to see 20+, but honestly don't think we'd get that from an acquirer.

100% agree. Stock price will rise based on future commentary and expectations. Nasrat usually keeps his cards close to his chest, so I'll be thrilled what he divulges instead of having to wait until June.

My comments were absolute floor, not upwards projection. Current price of 0.50 is both looking back on actual and some forward view and includes some of the revenue that will be captured. Stock market is forward looking

ChatGPT pulls a lot of fiction with fact. P/S would be way, way too high for starters. I'd expect closer to 3x, but depends on many variables.

To estimate the price per share of Elite Pharmaceuticals (ELTP) based on an annual revenue of $500 million, we can use the Price-to-Sales (P/S) ratio from their financial reports. The P/S ratio is calculated as:

\text{P/S Ratio} = \frac{\text{Market Cap}}{\text{Annual Revenue}}

From the search results, Elite Pharmaceuticals has a market cap of approximately $534.14 million and a revenue of $71.17 million for the last 12 months [A](https://www.marketbeat.com/stocks/OTCMKTS/ELTP/?copilot_analytics_metadata=eyJldmVudEluZm9fY2xpY2tEZXN0aW5hdGlvbiI6Imh0dHBzOlwvXC93d3cubWFya2V0YmVhdC5jb21cL3N0b2Nrc1wvT1RDTUtUU1wvRUxUUFwvIiwiZXZlbnRJbmZvX21lc3NhZ2VJZCI6IkVvYmVmRGZYaXlrVkZieHBGNWtuZCIsImV2ZW50SW5mb19jb252ZXJzYXRpb25JZCI6InFaczlTOUJUZEJYVjJkZ3VEYXJoeSIsImV2ZW50SW5mb19jbGlja1NvdXJjZSI6ImNpdGF0aW9uTGluayJ9&citationMarker=9F742443-6C92-4C44-BF58-8F5A7C53B6F1). However, since we're estimating based on $500 million revenue, we'll adjust the calculation accordingly.

First, let's find the P/S ratio:

\text{P/S Ratio} = \frac{534.14 \text{ million}}{71.17 \text{ million}} \approx 7.50

Now, using the P/S ratio to estimate the price per share:

\text{Estimated Price per Share} = \text{P/S Ratio} \times \text{Annual Revenue}

\text{Estimated Price per Share} = 7.50 \times 500 \text{ million} = 3,750 \text{ million}

Since the company has 1.07 billion shares outstanding:

\text{Estimated Price per Share} = \frac{3,750 \text{ million}}{1.07 \text{ billion}} \approx \$3.50

So, based on an annual revenue of $500 million, the estimated price per share of Elite Pharmaceuticals would be approximately **$3.50**.

Does this help with your analysis?

So your saying $70 million gets us $0.50 now
an additional $500 million ie. $570 million gets us another quarter ??

THX ?

Here are five generic pharmaceutical companies with a P/E ratio higher than 30:

1. **Cipla Limited** (India) - P/E ratio: 33.5
2. **Zoetis Inc.** (USA) - P/E ratio: 33.03
3. **Haleon plc** (UK) - P/E ratio: 29.06
4. **Neurocrine Biosciences, Inc.** (USA) - P/E ratio: 34.11
5. **Elanco Animal Health Incorporated** (USA) - P/E ratio: 32.02

Would you like more information on any of these companies or their financial performance?

They launched Vyvanve during the holidays, and with only a few days left in the quarter. Due to that I'm not expecting much numbers wise. I'm more interested in his guidance during the CC in February, and to see where we're at the following few quarters. A positive BE study or two is of equal interest to me. I like my cakes layered. 🤤

We were at $0.75 with $70 million in revenues.

No one knows anything until next quarter review where we will see how much vyvanse they were able to push since FDA approval. Once we figure this number out we will be able to calculate their quota and potential annual revenue from vyvanse

No one knows anything until next quarter review where we will see how much vyvanse they were able to push since FDA approval. Once we figure this number out we will be able to calculate their quota and potential annual revenue from vyvanse

If you can find a generics only company with no brand drugs that is in the 30's for a multiple, I would be ecstatic. 

weekend kool aide drinkers are drinking a ton of kool aide. Lets throw a 10 multiple on this now. LOL, never mind that $3 buyout, lets make it $7 or more. I got orange, fruit punch, and the new lemon lime flavor of kool aide. I also have a bridge to sell everyone who thinks this crazy OTC fantasy is going much higher. Please pay the Mikah tax first. Nothing will happen until this "cloud" gets lifted, otherwise its smooth sellilng to bagholders who think this is going to be bought out. Not happening!

PE ratio for generics should be around 30.

I saw multiple formulae on this board. This one is the lowest ever.

I can’t search them right now but I will post them when I am at my desktop.

Not following your comment. My comment was the absolute floor using a generic industry multiple of 8-12x is normal, which I used the absolute bottom.

Quick back of envelope math:
500M x 20% flow through NI / 1.1B shares x 8 multiple

Margins should be fantastic out of the gate, but will settle down. I wouldn't use a larger flow % to NI above 30% since generic competition will increase and it wouldn't be sustainable (and therefore not a long term assumption a buyer would use).

However, I have seen some PE companies make some idiotic acquisitions at crazy high multiples, but I think it's going to be a competitor that buys us out that really knows the market. 

Jour you are off I believe.

At 500 million in revenue we should be close to $5. Not .75

You are multiplying the revenue 10 times.

Our profit margin will go way up.

Sounds like it would be an absolute headache and minimal market in Japan. 

At absolute bare minimum share price would be at 0.75 with $500M in rev using 20% flow through rate (what we have been at for many quarters) and 8x multiple. That is only with a historical look back and excludes any margin pickup with new facility, machine and Vyvanse launch along with future growth.

I'd uncheck Accord/Elite prevailing over Purdue. Accord has, Elite has been accused of infringing other patents. 2 very different cases.